KVUE stock forecast: what analysts expect
Wall Street analysts covering Kenvue Inc. currently rate the stock a Hold on average, with a mean 12-month price target of $19.50 — -0.4% versus the last price of $19.57. Targets reflect analyst opinion, not a guarantee.
KVUE historical returns
Based on monthly dividend-adjusted prices. See the full breakdown on what if you had invested in KVUE.
KVUE annual returns by year
Congress trading in KVUE
7 members of Congress have disclosed trading KVUE — 6 purchases and 9 sales worth an estimated $144,500. Most recent disclosure: Aug 5, 2026.
See who in Congress traded KVUE →About Kenvue Inc.
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
KVUE Key Statistics
KVUE in plain English
- P/E ratio (22.8) — how many dollars you pay for each $1 of KVUE's yearly profit. That's a fairly normal range.
- ROE (15.58%) — how efficiently the company turns shareholders' money into profit. This is a middling level.
- Profit margin (10.76%) — of every $1 in sales, this is what's left as profit after all costs.
- Dividend yield (4.29%) — the cash payout you'd earn per year as a % of the share price, on top of any price gains.
KVUE stock: frequently asked questions
What is Kenvue Inc.'s stock price today?
Kenvue Inc. (KVUE) last traded at $19.57 on the NYSE. Over the past 52 weeks the stock has traded between $14.02 and $20.13.
Is KVUE stock a buy or a sell?
Wall Street analysts' consensus rating on KVUE is "Hold", with an average 12-month price target of $19.50 — about -0.4% versus the current price of $19.57. Analyst targets are opinions, not guarantees; always do your own research.
Does KVUE pay a dividend?
Yes. Kenvue Inc. currently pays a dividend yielding about 4.29% per year at today's share price.
What is KVUE's P/E ratio?
KVUE trades at a trailing price-to-earnings ratio of 22.8, and 15.8 times expected forward earnings. The P/E ratio tells you how many dollars investors pay for each $1 of the company's annual profit.
Do members of Congress trade KVUE stock?
Yes — 7 members of Congress have disclosed trades in KVUE under the STOCK Act, totaling 6 purchases and 9 sales worth an estimated $144,500.
What is Kenvue Inc.'s ticker symbol?
Kenvue Inc. trades under the ticker symbol KVUE on the NYSE.
Compare KVUE with peers
Data last refreshed from public sources. Figures may be delayed. Not investment advice.